Trial Profile
A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HMPL-504 in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Savolitinib (Primary)
- Indications Advanced breast cancer; Colorectal cancer; Gastric cancer; Liver cancer; Lung cancer; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors AstraZeneca; Hutchison MediPharma
- 05 Apr 2019 Results published in the Clinical Cancer Research
- 01 Aug 2016 According to Chi-Med and AstraZeneca media release, first patient dosed in Q1 2012.
- 31 May 2016 Status changed from recruiting to completed.